- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Drug Alert: 51 Drug samples fail to qualify CDSCO test
Overview
In its latest drug alert, the apex drug regulatory body, the Central Drugs Standard Control Organization (CDSCO), has flagged 51 medicine batches for failing to qualify for a random drug sample test for the month of July, while three drug samples have been declared spurious.
The list of Drugs declared as Not of Standard Quality includes Stadmed's Paracin Plus Suspension (Ibuprofen and Paracetamol Suspension), Hindustan Antibiotics' Ornidazole and Ofloxacin Tablets IP, Alves Healthcare's Rabeprazole Gastro-Resistant Tablets IP 20 mg, Zee Laboratories' Amoxycillin and Potassium Clavulanate Tablets I.P. 625 mg, Zenith Drugs' Cyproheptadine Hydrochloride Syrup IP (Hungree Syrup), and others.
For more details, check out the link given below:
Drug Alert: 53 Drug Samples Fail To Qualify CDSCO Test, 3 Declared Spurious